What causes ohss after embryo transfer

Overview

Ovarian Hyperstimulation Syndrome (OHSS) is a medical condition that can occur in women undergoing fertility treatments, particularly those involving ovulation induction. While it is a known risk associated with these therapies, understanding its causes, symptoms, and management is crucial for patients undergoing or considering assisted reproductive technologies (ART) like in vitro fertilization (IVF). The hormonal environment created during fertility treatments, especially the administration of human chorionic gonadotropin (hCG), plays a central role in the development of OHSS. This article delves into the specific triggers and mechanisms behind OHSS following an embryo transfer.

What is Ovarian Hyperstimulation Syndrome (OHSS)?

OHSS is a condition where a woman's ovaries become swollen and painful. It is an exaggerated response to fertility medications used to stimulate the ovaries to produce eggs. These medications, primarily gonadotropins (like FSH and LH), encourage the development of multiple follicles in the ovaries. A follicle is a sac containing an immature egg. In a natural cycle, usually only one follicle matures and releases an egg. In fertility treatments, the goal is to develop several mature follicles to increase the chances of successful fertilization and pregnancy. The final trigger for ovulation, and often for the development of OHSS, is the administration of hCG. This hormone mimics the natural LH surge that occurs before ovulation. In susceptible individuals, the ovaries overreact to the hCG, leading to excessive follicle development and the production of chemicals that cause the ovaries to swell and leak fluid.

The Role of hCG in OHSS after Embryo Transfer

The primary driver of OHSS after an embryo transfer is the hormone human chorionic gonadotropin (hCG). hCG is a hormone produced by the developing embryo shortly after implantation and is later produced in larger quantities by the placenta. It is the hormone detected in pregnancy tests. In fertility treatments, hCG is often administered as an injection to trigger final egg maturation and ovulation before egg retrieval for IVF. Following embryo transfer, if pregnancy occurs, the body naturally begins to produce its own hCG. This endogenous hCG then continues to stimulate the ovaries, which are already enlarged from the initial stimulation with gonadotropins. The sustained stimulation by hCG causes the ovaries to become even larger and more sensitive, leading to the characteristic symptoms of OHSS. The higher the level of hCG produced (indicating a more robust pregnancy or multiple pregnancies), the greater the risk and severity of OHSS.

Factors Contributing to OHSS Risk

Several factors can increase a woman's susceptibility to developing OHSS after an embryo transfer:

• Number of Follicles: A higher number of developing follicles in the ovaries before egg retrieval is a significant risk factor. This indicates a greater potential for overstimulation.
• Estrogen Levels: High estrogen levels, often measured during ovarian stimulation, are strongly correlated with the development of OHSS. Estrogen is produced by the developing follicles.
• Polycystic Ovary Syndrome (PCOS): Women with PCOS may be more sensitive to gonadotropin medications, increasing their risk of OHSS.
• Previous History of OHSS: If a woman has experienced OHSS before, her risk of developing it again in subsequent treatments is higher.
• Age: Younger women tend to be more sensitive to ovarian stimulation medications.
• Rapid Weight Gain: This can be an indicator of fluid accumulation, a key symptom of moderate to severe OHSS.

Mechanism of OHSS Development

The development of OHSS is a complex process involving multiple vasoactive substances. When the ovaries are overstimulated, they release various mediators, including vascular endothelial growth factor (VEGF). VEGF causes blood vessels in the ovaries to become more permeable, meaning they leak fluid. This fluid can accumulate in the ovaries, making them enlarge, and can also shift from the bloodstream into other body cavities, such as the abdomen (ascites) and the chest (pleural effusion). This fluid shift can lead to a decrease in the circulating blood volume, which can cause symptoms like dizziness, reduced urine output, and in severe cases, can strain the kidneys and lead to blood clots (thrombosis).

Symptoms of OHSS

OHSS can manifest in varying degrees of severity:

• Mild OHSS: Usually appears 3-7 days after hCG administration or embryo transfer if pregnancy occurs. Symptoms include mild abdominal discomfort, bloating, nausea, and mild ovarian enlargement. These symptoms often resolve on their own within a week or two.
• Moderate OHSS: Symptoms are more pronounced and may include significant abdominal pain, vomiting, diarrhea, and noticeable abdominal distension due to fluid buildup. Ovarian enlargement is more significant.
• Severe OHSS: This is a medical emergency and can develop rapidly. Symptoms include severe abdominal pain, persistent nausea and vomiting, rapid weight gain (over 10 pounds in 3-5 days), shortness of breath, chest pain, decreased urine output, and signs of blood clots (leg pain, swelling). Ovarian enlargement can be extreme, and significant fluid accumulation in the abdomen and chest can occur. Severe OHSS can lead to complications such as electrolyte imbalances, kidney failure, blood clots (pulmonary embolism), and in rare cases, death.

Management and Prevention

The management of OHSS depends on its severity. Mild cases can often be managed at home with rest, hydration, and pain relief. Moderate to severe cases require hospitalization for monitoring, intravenous fluids, and potentially medications to manage symptoms and prevent complications. Prevention strategies are paramount and include careful monitoring of ovarian response during stimulation, adjusting medication doses, choosing a trigger shot other than hCG (like GnRH agonists) in high-risk patients, and sometimes freezing all embryos and delaying transfer until the risk of OHSS has passed.

Conclusion

OHSS after embryo transfer is a complex but generally manageable complication of fertility treatments. The key causative factor is the hormonal stimulation, particularly by hCG, which leads to an exaggerated response of the ovaries. Recognizing the risk factors, understanding the symptoms, and adhering to medical advice are crucial for patients undergoing IVF. While OHSS can be distressing, prompt diagnosis and appropriate management significantly improve outcomes and ensure the safety of the patient.